eGFP-transduced marrow cells) or in vitro CTL responses in the recipients. These findings, coupled with those of Denaro et al 7 (vide infra), suggest that eGFP is not highly immunogenic in C57BL/6 mice.
Clearly, eGFP is immunogenic in Balb/c mice and, as reported recently, in rhesus macaque monkeys. 3 The lack of immunogenicity of this protein in C57BL/6 mice may be an exception rather than the rule. C57BL/6 mice have also been noted to have relatively weak immunologic responses to adenoviral vector proteins and human factor IX protein, compared with a number of other mouse strains. [4] [5] [6] Our original caution pertaining to the use of eGFP as a selectable marker for in vivo studies, especially those intended for human subjects remains valid. We now propose the additional caution that eGFP may be a poor indicator of immune responses or induction of tolerance to transgene products in C57BL/6 mice. In particular, syngeneic tumor cells transduced with retroviral (RV) vectors expressing EGFP have been reported to be rejected following transplantation in immunocompetent C57BL/6 and BALB/c recipients. 1 In the BALB/c mouse strain, the mechanism for rejection of CMS4 sarcoma and BM185 leukemia cells has been shown to be mediated by cytotoxic T-lymphocytes (CTLs) that recognize the foreign EGFP peptides.
1,2 Furthermore, CTL responses have been observed in rhesus monkeys receiving a low nonmyeloablative dose of radiation and EGFP-transduced autologous hematopoietic cells. 3 Attracted by the technical ease of using rejection in a solid tumor model for studying immunological tolerance, our laboratory has conducted a set of experiments using EL-4 T cell lymphoma cells growing in C57BL/6 mice, similar to those described by Stripecke et al. 1 Briefly, EL-4 cells (ATCC, Rockville, MD, USA) were transduced with a RV vector denoted GBiP. This vector contains an EGFP (G) cDNA followed by the human immunoglobulin heavy chain binding protein (BiP) which is an internal ribosomal entry site (IRES) inserted in a pLN 4 backbone modified with a myeloproliferative sarcoma virus (MPSV) enhancer in the 3'LTR. 5 The plasmid pGBiP-6 was deposited with the ATCC (No. PTA 2498).
An EGFP + EL-4 clone (EL4xEGFP) was established that has stable EGFP expression with a mean fluorescence intensity of approximately 1000-fold above nontransduced wild-type (wt) cells. Additionally, EL-4 cells expressing the marker neo were established (EL4-neoR) by transduction with an amphotropic pLXSN 4 vector and selection in 1 mg/ml G418. A neo-resistant pool of the EGFP+ EL-4 clone was established also by transduction with pLXSN (EL4xEGFP-neoR).
In four separate experiments using a dose of 5 × 10 antibody (Clone KH95; PharMingen, San Diego, CA, USA) and found to be equivalent to wt EL-4 cells. We reasoned that the detection of immunological rejection might depend on the size of the tumor cell inoculum. However, this did not appear to be a significant factor as a lack of growth inhibition of EGFP-transduced EL-4 cells, as compared with the wt cells was also seen at lower cell doses (Figure 1) . In a separate experiment, neoR-transduced EL-4 cells, with or without co-transduction with EGFP, all formed tumors. Therefore, our results appear to be at variance with the previous findings of Stripecke et al 1 who reported that three mice inoculated with EL-4 cells containing both neomycin resistance and EGFP genes failed to develop tumors. We would con- Gene Therapy clude that the use of EL-4 T cell lymphoma cells implanted in C57BL/6 mice is not consistently applicable as a model for demonstrating immunological rejection due to expression of neomycin resistance and EGFP as foreign genes. A possible explanation for our negative results with this particular tumor and mouse strain is that the antigen presentation of EGFP and neoR-derived peptides by C57BL/6 H-2D b molecules may be deficient as compared with BALB/c H-2K d molecules.
